Negative Symptoms of Schizophrenia: What Treatment Does

The negative symptoms of schizophrenia are blunted affect, alogia, asociality, anhedonia, and avolition.¹ In a 2015 meta-analysis of 168 randomized placebo-controlled trials, most treatments reduced negative symptoms relative to placebo, and none reached the threshold for clinically significant improvement.²

A 2026 meta-analysis of 451 trials with 42,566 participants partly revises that conclusion. It found several treatment subcategories above its threshold for a clinically meaningful effect, including add-on antidepressants and physical activity, with evidence grades that ranged from high to very low.³

The five domains of negative symptoms

The NIMH-MATRICS consensus statement lists these five domains and notes evidence that blunted affect and poverty of speech form one grouping, while anhedonia, asociality, and avolition may form another.¹

A 2026 meta-analysis glosses each term: blunted affect ("reduced expression of emotion"), alogia ("poverty of speech"), asociality ("lack of interest in social interactions"), anhedonia ("reduced ability to experience pleasure"), and avolition ("reduced initiation and persistence in goal-directed activities").³

How common they are depends on the definition

In 1,452 outpatients with schizophrenia spectrum disorders who were taking antipsychotics, 57.6% had one or more negative symptoms and 12.9% had primary negative symptoms.⁵

In an analysis of clinical trial samples, 8.1% of patients met one set of criteria for prominent negative symptoms and 62.3% met another.⁶

Primary versus secondary negative symptoms

Primary negative symptoms are thought to be intrinsic to schizophrenia. Secondary negative symptoms are caused by positive symptoms, depression, medication side effects, social deprivation or substance abuse.⁷ A 2017 review in World Psychiatry recommends that symptoms due to identifiable factors, such as medication effects, psychotic symptoms or depression, be distinguished from those regarded as primary.⁴

European Psychiatric Association guidance states that antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and to positive symptoms.⁹ That adjustment belongs with the prescriber, and a dose or drug shouldn't be changed without one.

Negative symptoms also change over time. In a meta-analysis of longitudinal data, they declined in every study condition, including placebo and treatment as usual, with a medium effect size of 0.66.⁸

What antipsychotics do for negative symptoms

Across 167 placebo-controlled trials in 28,102 participants with acute schizophrenia, antipsychotics improved negative symptoms (standardized mean difference 0.35) less than positive symptoms (0.45).¹⁰ Those trials can't separate primary negative symptoms from improvement that follows less psychosis. I've written separately about schizophrenia and psychosis treatment.

A 2018 meta-analysis of 21 randomized trials with 3,451 participants looked only at patients with predominant or prominent negative symptoms. Amisulpride was superior to placebo in four trials with 590 patients (standardized mean difference 0.47; 95% CI, 0.23 to 0.71). The authors wrote that it "is the only antipsychotic that outperformed placebo in the treatment of predominant negative symptoms, but there was a parallel reduction of depression."¹¹ A 2020 review notes that low-dose amisulpride is approved for negative symptoms in a limited number of European countries.¹⁴

Cariprazine compared with risperidone

One trial randomized 461 patients with predominant negative symptoms to cariprazine or risperidone for 26 weeks. The negative symptom factor score fell by 8.90 points with cariprazine and 7.44 points with risperidone, a difference of 1.46 points in favor of cariprazine (95% CI, 0.53 to 2.39; effect size 0.31). The trial was funded by Gedeon Richter.¹²

Antidepressants added to an antipsychotic

A meta-analysis of 82 randomized trials with 3,608 participants found a benefit of add-on antidepressants for negative symptoms (standardized mean difference 0.30; 95% CI, 0.16 to 0.44), which the authors called small, beneficial effects.¹⁵

A second meta-analysis narrowed that finding. The benefit for negative symptoms was confirmed in studies augmenting first-generation antipsychotics (standardized mean difference 0.42) and wasn't significant with second-generation antipsychotics (P = 0.144). The authors concluded that negative symptom improvement "seems restricted to the augmentation of FGAs."¹⁶

Psychosocial treatment and exercise

Social skills training was superior to treatment as usual and to active controls for negative symptoms, with effect sizes of 0.2 to 0.3.¹⁷ The European guidance recommends it, along with cognitive remediation for patients who also show cognitive impairment.⁹

The evidence on cognitive behavioral therapy (CBT) conflicts. A meta-analysis of 30 trials in 2,312 patients found no significant effect in studies focused on negative symptom reduction (Hedges' g 0.157; p = 0.225).¹⁸ Two other meta-analyses found that CBT outperformed treatment as usual, one with a pooled standardized mean difference of 0.34 in favor of CBT and one, in six studies of patients with relevant negative symptoms, with an effect size of 0.46.^{19, 20}

Aerobic exercise had a small beneficial effect in a meta-analysis of 17 randomized trials with 954 patients, and the included studies didn't assess patients for predominant or primary negative symptoms.²¹ A 2023 review of 31 systematic reviews rated most of them very low to low in methodological quality.²²

Is there an FDA-approved medication for negative symptoms?

As of the 2020 review, "to date no agent is approved by the FDA for the treatment of negative symptoms."¹⁴ The cariprazine label (version effective December 18, 2025) lists treatment of schizophrenia in adults and in pediatric patients 13 years and older, with no separate indication for negative symptoms.¹³

A 2025 paper describes roluperidone as a drug in development for primary negative symptoms.²³ In a phase 3 trial of add-on pimavanserin in patients with predominant negative symptoms, the change at week 26 was not significantly different from placebo (P = .48; effect size 0.07).²⁴

Whether the effects are large enough to matter

The 2015 meta-analysis found no treatment above its threshold.² The 2026 analysis set its threshold at a standardized mean difference of 0.457. In 214 high-quality studies, the subcategories above it were antibiotics (0.95; moderate grade), integrated psychosocial interventions (0.93; very low), antidepressants (0.76; moderate), physical activity (0.68; very low), transcranial current stimulation (0.52; low), and immunomodulators (0.47; high), typically as adjuncts to antipsychotics. The authors named heterogeneity as the main limitation and concluded that selected interventions may yield meaningful improvements, with more rigorous designs needed.³

Limitations of the evidence

This evidence has limitations. First, most trials didn't select for primary negative symptoms, so improvement may reflect less depression, less psychosis or fewer side effects. Second, the cariprazine result rests on a single manufacturer-funded trial, and the controlled drug data here stop at 26 weeks. Nevertheless, the 2017 review and the European guidance both call for attention to secondary causes.

None of the sources gathered for this page on November 12, 2026 shows a single treatment that resolves negative symptoms. The European guidance lists options to discuss with the psychiatrist: optimizing the current antipsychotic, an add-on antidepressant, and social skills training.⁹

In a crisis: call or text 988, or go to the nearest emergency department. A first episode of psychosis belongs in a hospital-based or coordinated specialty care program.

I start and manage clozapine in an outpatient practice in Chelsea, Manhattan. Details are on the schizophrenia care in NYC page. Clozapine should not be stopped, skipped, or restarted without the prescriber. This page is general information and does not replace an evaluation.

Related: Schizophrenia and psychosis treatment guide · When to start clozapine · Clozapine blood tests after the REMS ended · Clozapine side effects · Missed clozapine doses · Clozapine and suicide risk · Cannabis and psychosis · Schizoaffective vs schizophrenia · Cobenfy vs clozapine · Postpartum psychosis · Injections vs pills · Stimulants and psychosis · Drug-induced psychosis · Clozapine levels · CBT for psychosis · Clozapine myocarditis · Cannabis after psychosis · Clozapine constipation · Work and school · Clozapine drooling · Early signs in teens · Clozapine weight gain · Genetic and family risk · Who can prescribe clozapine · Schizophrenia and violence · Clozapine in teenagers · Sleepiness, bedwetting, heart rate · When clozapine isn't enough · Clozapine interactions · Benign ethnic neutropenia · Clozapine off-label uses · Starting clozapine · Clozapine and pneumonia · Clozapine seizures · Clozapine in pregnancy · Clozapine rechallenge · Relative refuses treatment · Late-onset schizophrenia · First-episode psychosis · Tardive dyskinesia · Stopping antipsychotics · Schizophrenia life expectancy · Key clozapine studies